Table 1. Characteristics of patients in the discovery and validation cohorts.
| Characteristics | Discovery cohort | Validation cohort |
|---|---|---|
| Age, median (range), years | 59 (25–81) | 65 (32–82) |
| Gender, n (%) | Male, 51 (52.6) | Male, 141 (59.5) |
| Female, 46 (47.4) | Female, 96 (40.5) | |
| TNM, n (%) | II, 0 (0) | II, 65 (27.4) |
| III, 97 (100) | III, 102 (43.0) | |
| IV, 0 (0) | IV, 70 (29.5) | |
| Location, n (%) | Left colon, 48 (49.5) | Left colon, 155 (65.4) |
| Right colon, 49 (50.5) | Right colon, 69 (29.1) | |
| Grade, n (%) | Low (grade 1–2) 68 (70.1) | Well, moderate, 140 (96.5) |
| High (grade 3–4) 29 (29.9) | Poor, 5 (3.5) | |
| Mucinous, n (%) | – | Yes, 25 (16.3) |
| – | No, 128 (83.7) | |
| MMR statusa, n (%) | Deficient 10 (10.3) | Deficient 19 (7.0) |
| Proficient 87 (89.7) | Proficient 249 (91.9) | |
| Follow-up in all patients, median (range) | 3.2 (Range: 0.35–7.1 years) | 4.4 (Range: 0.24–14.4 years) |
Abbreviations: MMR=mismatch repair; TNM=tumour, node, metastasis.
a
DNA status was determined by MMR protein expression in the discovery cohort and MSI testing in the validation cohort.